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Abstract
Objective—To assess the appropriateness
of indications for coronary artery bypass
graft (CABG) surgery and percutaneous
transluminal coronary angioplasty
(PTCA).
Methods—A modified Delphi group
judgement process with input from a
panel of six interventional cardiologists
and six cardiopulmonary surgeons. There
was one clinician from each of the 12 ter-
tiary referral heart centres in The
Netherlands.
Main outcome measure—Ratings by
panel members, on a 1 to 9 scale, of indi-
cations presented as a choice between two
treatments (CABG v medical treatment,
PTCA v medical treatment, and CABG v
PTCA) for 1182 model cases. Each case
represented a unique combination of clin-
ical features in terms of symptoms, med-
ical history, and results of tests. Ratings
were analysed with respect to degree of
agreement among panelists, degree of
appropriateness of indications, and
panel’s preference for invasive or medical
treatment.
Results—The panel agreed on 58·6% and
disagreed on 3·2% of the indications. The
panel opted for invasive treatment in
48·2% and medical treatment in 22·8%,
and had no clear preference for either
method in 29·0% of the cases. When com-
pared with medical treatment, CABG was
more often rated appropriate than PTCA:
35·4% v 21·6% (P < 0·001). Panel scores
depended on severity of anatomical dis-
ease. For instance, for 51·5% of the model
cases with one-vessel disease not includ-
ing the proximal left anterior descending
artery, the panel preferred medical treat-
ment to invasive treatment, while the lat-
ter was preferred in 18% of the cases. In
cases with type C lesions, the panel fre-
quently rated PTCA as inappropriate.
Panel scores were also affected by non-
clinical factors. Cardiologists and sur-
geons rated the procedure of their own
specialty higher than the alternative inva-
sive intervention.
Conclusions—The panel method yields
logically consistent scores of the appro-
priateness of indications for carrying out
medical procedures. It may be an aid in
formulating clinical practice guidelines.
(Heart 1997;77:211–218)
Keywords: coronary artery bypass grafting; percuta-
neous transluminal coronary angioplasty; indications;
appropriateness
The provision of “appropriate care” has been a
priority on the political agenda in The
Netherlands since 1992, when the government
published a white paper on the subject, but
there is confusion among policy makers about
what it means.1 We consider care appropriate
when the benefits of using a medical proce-
dure exceed the risks, exclusive of monetary
cost.2 3 Central to determining appropriateness
of care is identifying appropriate reasons, or
indications, for carrying out the procedure.
Determining the appropriateness of indica-
tions is not seen in The Netherlands as a tool
for health insurance companies to limit the
cost of health care, but primarily as an aid for
physicians and other health care workers to
verify and enhance the quality of their profes-
sional decisions.
Assessments of the appropriateness of indi-
cations should ideally be based on the evi-
dence in published work on the risks 
and benefits of applying the procedure. Unfor-
tunately, for most procedures there are many
possible indications for which this information
is incomplete, inconsistent, or out of date. A
commonly used method for dealing with the
deficiencies of outcome results in the literature
is the RAND/UCLA appropriateness method,
which requires a panel of experts to review the
published reports thoroughly and then to rate,
in two rounds, the appropriateness of indica-
tions for carrying out a medical procedure.
This method presumes that experienced
physicians can use clinical insights to supple-
ment the published reports.2–4 Panel scores can
be used to evaluate the appropriateness of
treatment decisions in everyday practice.
The RAND/UCLA method has been
applied to a variety of medical procedures.4–6
Since 1988 panels in the USA, the United
Kingdom, The Netherlands, Canada, and
Sweden have determined the appropriateness
of indications for coronary artery bypass graft
(CABG) surgery and percutaneous translumi-
nal coronary angioplasty (PTCA) for patients
with coronary artery disease.6–10 We describe
here the views of the Dutch panel. In addition,
we present findings from analyses aimed at
identifying clinical and non-clinical determi-
nants of the panel scores. In a second paper11
we report on the appropriateness of treatment
decisions in coronary artery disease, in 10 ter-
tiary referral centres in The Netherlands. This
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work is part of the DUCAT (Dutch inventory




In The Netherlands invasive cardiovascular
interventions such as CABG and PTCA are
carried out exclusively in specialised heart cen-
tres on the basis of a permit issued by the gov-
ernment. At the start of the DUCAT study, in
1991, there were 12 heart centres, seven form-
ing part of university hospitals and five of non-
university hospitals. We asked 12 prominent
experienced clinicians, one from each centre,
to participate in the panel. They all accepted
the invitation. Six (including the only woman)
were cardiopulmonary surgeons and six were
interventional cardiologists. Unlike similar
panels in the USA, Canada, and Sweden7–10
our panel did not include internists or primary
care practitioners, as these physicians usually
do not refer patients to heart centres in The
Netherlands. The panelists varied in age
(34–53 years), number of years since specialist
registration (3–19), and school of specialist
training, but not in volume of invasive cardio-
vascular procedures personally performed (at
least 100 in 1991). They were instructed to
give their best personal clinical judgement and
not to try to represent the position of their
centre or specialty. The panelists took part in
all steps of the RAND/UCLA method. They
were provided with reviews of publications
from 1971 to 1991 on the effectiveness and
risks of CABG and PTCA, and with the report
of the American College of Cardiology/
American Heart Association task force on
bypass surgery.7 8 14
SET OF THEORETICAL INDICATIONS
A fundamental step in the RAND/UCLA
method is to develop a comprehensive list of
model cases. In drawing up the initial list we
used as guides the reviews of published reports,
experience from previous panels, and feedback
from our panelists. We identified eight mutu-
ally exclusive “chapters” of model cases with
significant coronary artery disease according to
presenting symptoms or problems: (1) asymp-
tomatic, (2) chronic stable angina, (3) unstable
angina, (4) acute myocardial infarction, (5)
recent myocardial infarction, (6) near sudden
death, (7) CABG carried out with valve
surgery, and (8) PTCA as palliative treatment
in patients with non-cardiac terminal disease.
(For definitions see the appendix.) Within each
clinical chapter, model cases were charac-
terised by unique combinations of clinical fea-
tures in terms of symptoms, medical history,
and the results of diagnostic tests. Although
the chapters defined were identical to those
identified by panels in other countries,7–10 the
panels did not end up with exactly the same
number of model cases and indications
because of generally minor differences in num-
ber of clinical features, and number of levels
per feature, selected.
An example of a model case is a patient with
chronic stable angina on mild exertion (that is,
Canadian Cardiovascular Society class III),
who is receiving adequate medication (that is,
a β blocker, calcium channel antagonist, and
nitrate, unless contraindicated), has two-vessel
disease not including the proximal left anterior
descending artery (PLAD) with at least one
stenosis being a type C lesion,15 has evidence of
ischaemia on an exercise stress test, has severe
left ventricular dysfunction, and is at high risk
for significant postoperative complications
according to the Parsonnet index.16 Examples
of type C lesions are stenoses longer than 20
mm, or with rugged contours or tortuous
shape, or located at spots not readily accessible
for a catheter, or total vessel occlusions older
than three months. For other definitions see
the appendix.
For most model cases the DUCAT panel
rated three indications, presented as a choice
between two treatments, namely: (1) CABG v
medical treatment, (2) PTCA v medical treat-
ment, and (3) CABG v PTCA. For the chap-
ters “CABG with valve surgery” and “palliative
PTCA”, the panel rated only CABG v medical
treatment and PTCA v medical treatment,
respectively. There were 1658 model cases and
4890 indications in the initial round of ratings.
Sheets were prepared on which the panelists
could rate each indication on a scale ranging
from 1 (extremely inappropriate) to 9
(extremely appropriate). The sheets, which
had the form of a long tabular list with the
rows presenting model cases and individual
cells the indications, were mailed to the pan-
elists, who individually completed the ratings
(round 1). One and a half months later, in
August 1991, the panelists convened for a two
day meeting (round 2) to discuss issues ema-
nating from round 1 and to rerate the indica-
tions confidentially. In both rounds the
panelists were instructed to rate each indica-
tion keeping in mind average cases in the aver-
age practice in the heart centres in The
Netherlands. That practice implies that refer-
ring cardiologists who have diagnosed coro-
nary artery disease in a patient present the
findings, including the coronary angiogram, to
an interventional cardiologist or cardiopul-
monary surgeon or both. This presentation
may be made either in person or by referral let-
ter or telephone.
The results of round 1 were precirculated
before the DUCAT panel met for round 2.
Each panelist received, for each indication, the
anonymous ratings of all the other panelists,
along with a reminder of his or her own rating.
During the panel meeting the indications were
discussed, concentrating on areas where the
panelists disagreed. The primary purpose of
the discussion was to ensure that panelists had a
shared understanding of the type of cases
described. Thus any remaining disagreements
would represent different treatment philoso-
phies. The panel refined some of the defini-
tions and revised the indications list, leaving a
total of 1182 model cases and 3446 indica-
tions. After discussing each clinical chapter,
the panelists rated anew the appropriateness of
each indication.
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Three months after the panel meeting, the
panelists were sent a set of indications (66 in
total) randomly selected from the first six clin-
ical chapters. The panelists were asked to
rerate these indications in the same way as
they had done in round 2. Eleven panelists
returned the completed rating sheets.
ANALYSIS
The ratings were analysed on two partly inter-
dependent dimensions: degree of agreement
among panelists and degree of appropriate-
ness. The scale was divided into three 3-point
regions, 1–3, 4–6, and 7–9. Agreement was
defined as at least nine of the ratings laying in
one of these regions. By definition there was
disagreement if the ratings of the panelists
were split, with four or more falling in each of
the two outer regions. In all other cases, the
panel was said to be indeterminate. The
appropriateness score for each indication was
taken as the median of the ratings of the pan-
elists.5 8 9 When comparing CABG or PTCA
with medical treatment, the invasive treatment
was appropriate if the median score was 7 to 9,
inappropriate if the median score was 1 to 3,
and uncertain if that score was 4 to 6 or if
there was disagreement among the panelists.
For CABG v PTCA indications the appropri-
ateness score 7 to 9 meant that surgery was
preferred to angioplasty, and 1 to 3 that angio-
plasty was preferred. Ratings and reratings
were defined as matching each other if they lay
in the same 3-point region. Test-retest concor-
dance was assessed with the κ statistic.17
Comparison of the scores between the two
rounds was only done on indications common
to both rounds. The analysis was restricted to
clinical chapters 1 to 6, that is, the chapters
with all three sets of indications. The results of
the comparison were displayed in 3 # 3 con-
tingency tables and analysed with the test of
marginal symmetry.18
Clinical and non-clinical determinants of
appropriateness scores were assessed for each
chapter with the least squares regression
model, with the median of the ratings of the
panelists, or subset of panelists, being the
dependent variable for each indication.
Results
Although no attempt was made to reach con-
sensus, agreement among the panelists
increased from 48·1% for the PTCA v medical
treatment indications in round 1 to 61·7% in
round 2, partly as a result of improved under-
standing of the rating process.19 Conversely,
disagreement for these indications fell from
7·9% to 3·8% and indetermination from
48·6% to 34·5%. Similar changes occurred for
the two other sets of indications, CABG v
medical treatment and CABG v PTCA (χ2 %
161·7; df 2; P < 0·001). For the three sets
together the DUCAT panel agreed in round 2
on 58·6% and disagreed on 3·2% of the indi-
cations. Appropriateness scores also changed
from round 1 to round 2, although to a lesser
degree (for the three sets of indications
together, χ2 % 41·4; df 2; P < 0·001). The
number of indications where CABG or PTCA
was judged appropriate compared with med-
ical therapy rose by approximately 4·5% in
both cases, while the number where CABG or
PTCA was considered inappropriate
decreased by 2·0% and 1·5%, respectively.
The number of CABG v PTCA indications
with clear preference for either surgery or
angioplasty increased by 2·4%.
Test-retest concordance for the sample 
of 66 indications was significant (κ % 0·72;
P < 0·001). Ten retest scores differed from the
original scores by 2 points, the maximum dif-
ference seen.
In the second round of ratings, CABG was
considered appropriate when compared with
medical treatment in 35·4% and inappropriate
in 36·5% of the cases. The corresponding fig-
ures for PTCA were less favourable: 21·6%
appropriate and 55·4% inappropriate.
Appropriateness scores varied by clinical chap-
ter (table 1). For clinical chapters where both
CABG and PTCA were considered, appropri-
ateness scores were highest for predominantly
urgent conditions: unstable angina, acute
myocardial infarction, and near sudden death.
Performing these procedures was considered
inappropriate in many of the cases which were
asymptomatic, had chronic stable angina, or
had a recent myocardial infarction.
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Table 1 Appropriateness of indications for coronary revascularisation and preferred treatment by clinical chapter¶
CABG v MED indications PTCA v MED indications Preferred treatment#
————————————— ————————————— ———————————
Chapter@ Appropriate Inappropriate Appropriate Inappropriate Invasive Medical
1 Asymptomatic (96) 30·2% 53·1% 7·3% 77·1% 35·4% 41·7%
2 Chronic stable angina (480) 24·8% 48·8% 14·8% 59·8% 34·4% 31·9%
3 Unstable angina (144) 57·6% 13·2% 40·3% 36·8% 78·5% 2·8%
4 Acute myocardial 
infarction (68) 39·7% 16·2% 35·3% 22·1% 64·7% 5·9%
5 Recent myocardial 
infarction (248) 36·3% 36·7% 14·1% 65·7% 44·4% 25·8%
6 Near sudden death (96) 53·1% 8·3% 29·2% 57·3% 72·9% 4·2%
7 CABG and valve surgery (2) 100·0% 0·0% — — 100·0% 0·0%
8 Palliative PTCA (48) — — 66·7% 16·7% 66·7% 0·0%
Total (1182) 35·4% 36·5% 21·6% 55·4% 48·2% 22·8%
¶Data are percentages of the total number of indications for either CABG v medical therapy, PTCA v medical treatment, or
preferred treatment. Number of model cases in parentheses.
#Invasive treatment was preferred to medical treatment when CABG and/or PTCA were rated appropriate. Medical treatment was
preferred when both CABG and PTCA were rated inappropriate.
@Clinical chapters were defined by presenting symptoms or problems. For definitions see Appendix.
—Not applicable.
CABG, coronary artery bypass grafting; MED, medical treatment; PTCA, percutaneous transluminal coronary angioplasty.
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The fact that CABG and PTCA were fre-
quently rated inappropriate when compared
with medical treatment does not necessarily
imply that the panel preferred medical treat-
ment. There were many model cases for which
the panel judged CABG to be inappropriate
but PTCA appropriate, or the other way
round. In these cases, and when both CABG
and PTCA were rated appropriate, the panel
obviously preferred invasive treatment to med-
ical treatment. On the other hand, medical
treatment was preferred to invasive treatment
when both CABG and PTCA were rated inap-
propriate for a model case. Overall the panel
opted for invasive treatment in 48·2% of the
model cases, while medical treatment was pre-
ferred in 22·8% of the cases. For the remain-
ing 29·0% of the model cases the panel did not
express a preference for either invasive treat-
ment or medical treatment (table 1).
As anatomical disease became more severe
in the model cases, the panel increasingly pre-
ferred invasive treatment to medical treatment
(table 2). The panel opted for invasive treat-
ment in 18·0% of the model cases with one-
vessel disease not including the PLAD,
compared with 94·0% of the cases with left
main disease. One-vessel disease involving the
PLAD was seen as a stronger reason for inva-
sive treatment than two-vessel disease not
involving the PLAD. At the same time the
number of cases where medical treatment was
preferred decreased as vessel disease became
more severe, from 51·5% in one-vessel disease
not including the PLAD to 0% in left main
disease. Table 3 shows the preference of the
panel for CABG or PTCA in model patients
for whom invasive treatment was preferred to
medical treatment. There was near absolute
preference for surgery in left main disease,
while the panel had few doubts that PTCA
was to be preferred in one-vessel disease. In
two-vessel disease angioplasty was favoured,
particularly in cases without PLAD stenosis.
CLINICAL FACTORS BEARING ON PANEL SCORES
The aggregate figures presented so far provide
only limited insight into the considerations
underlying the appropriateness scores.
Therefore we developed regression models to
explain the median panel ratings. For brevity
we only present the results for the three sets of
480 indications for the model cases with
chronic stable angina (table 4). Severity of
coronary artery disease, anginal symptoms,
extent of medical treatment, and degree of
peri-interventional risk were significantly
related to appropriateness scores for all three
sets of indications. For CABG v medical treat-
ment indications the lesion characteristic of
the coronary artery stenosis (type A, B, or C)
made no difference, in contrast to both PTCA
v medical treatment and CABG v PTCA indi-
cations. The outcome of an exercise stress test
and the degree of left ventricular dysfunction
were important for choosing between either
type of invasive intervention and medical
treatment, but they were not significant factors
for choosing between CABG and PTCA.
To illustrate the data in table 4 we take as
an example a model patient who suffers from
two-vessel disease not including the PLAD,
has class II angina, is on adequate medication,
has a positive exercise stress test, who does not
have severe left ventricular dysfunction (that
is, ejection fraction is ¢ 20%), and whose risk
of significant peri-interventional complications
is not high. For this case both CABG and
PTCA were rated uncertain when compared
with medical treatment, that is, the appropri-
ateness score lay in the middle range (4 to 6)
of the rating scale (see “constant” in table 4).
For CABG v medical treatment indications
the appropriateness score was 4·8 regardless of
lesion type. Lesion type did matter in PTCA v
medical treatment indications, the score being
5·8 if the lesion was type A or B and 2·7
(5·8 – 3·1) if type C. If an invasive procedure
was to be done, the DUCAT panel preferred
PTCA to CABG, as suggested by the constant
score of 2·8. When the model case had left
main disease preference swayed to CABG (2·8
+ 5·0 % 7·8), while in one-vessel disease the
score fell by 0·7 points (2·8 – 0·7 % 2·1).
NON-CLINICAL FACTORS
Appropriateness scores were also affected by
non-clinical factors. Age, years since specialist
registration, and school of specialist training of
the panelists did not influence the scores, but
specialty (surgeon or cardiologist) did.
Summed over all of the clinical chapters, sur-
geons rated slightly more CABG v medical
treatment indications appropriate than cardiol-
ogists (37·3% v 34·9%; χ2 % 5·65; P < 0·01)
and slightly fewer of these indications inap-
propriate (34·2% v 37·3%; χ2 % 6·92;
P < 0·001). The two specialties differed most
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Anatomical disease Invasive Medical None
One-vessel, "PLAD 36 (18·0) 103 (51·5) 61 (30·5)
One-vessel, !PLAD 80 (40·0) 59 (29·5) 61 (30·5)
Two-vessel, "PLAD 52 (26·0) 71 (35·5) 77 (38·5)
Two-vessel, !PLAD 99 (49·5) 30 (15·0) 71 (35·5)
Three-vessel 110 (65·5) 2 (1·2) 56 (33·3)
Left main 158 (94·0) 0 (0·0) 10 (6·0)
¶Numbers (%) of model cases for which the panel opted for invasive or medical treatment.
Invasive treatment was preferred to medical treatment when CABG and/or PTCA were rated
appropriate. Medical treatment was preferred when both CABG and PTCA were rated
inappropriate. None of the treatments was preferred if neither invasive nor medical treatment
was preferred to the other treatment.
CABG, coronary artery bypass grafting; PTCA, percutaneous transluminal coronary angio-
plasty; !PLAD and "PLAD, with and without involvement of the proximal left anterior
descending coronary artery, respectively.




Anatomical disease n CABG PTCA Both
One-vessel, "PLAD 36 0·0% 97·2% 2·8%
One-vessel, !PLAD 80 6·3% 75·0% 18·8%
Two-vessel, "PLAD 52 7·7% 78·8% 13·5%
Two-vessel, !PLAD 99 29·3% 44·4% 26·3%
Three-vessel 110 65·7% 0·0% 34·3%
Left main 158 98·7% 0·0% 1·3%
¶Limited to model cases (n = number) for which the panel preferred invasive treatment to
medical treatment. “Both”: cases where both CABG and PTCA were appropriate compared with
medical treatment and where CABG was not preferred to PTCA or vice versa.
CABG, coronary artery bypass grafting; PTCA, percutaneous transluminal coronary angio-
plasty; !PLAD and "PLAD, with and without involvement of the proximal left anterior
descending coronary artery, respectively.
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regarding the PTCA v medical treatment indi-
cations. Surgeons rated fewer of these indica-
tions appropriate and more of them
inappropriate than cardiologists (18·4% v
25·7%, χ2 % 59·7, and 59·1% v 48·8%, χ2 %
84·6, respectively; P < 0·001). On average,
surgeons were more critical of PTCA v med-
ical treatment indications than cardiologists
were of CABG v medical treatment indica-
tions.
Considering only clinical chapters 1–6, the
tendency of the surgeons to rate PTCA v med-
ical treatment indications lower than the cardi-
ologists was significant for the chronic stable
angina, unstable angina, acute myocardial
infarction, and recent myocardial infarction
chapters. The picture for CABG v medical
treatment indications was more variable. The
surgeons rated these indications significantly
higher than the cardiologists did for the clini-
cal chapters “asymptomatic”, “unstable
angina”, and “near sudden death”, but lower
for “chronic stable angina” and “acute
myocardial infarction”. The pattern of results
for acute myocardial infarction was particu-
larly noteworthy. Here the surgeons rated both
PTCA v medical treatment and CABG v
medical treatment indications lower than the
cardiologists, which suggests that they had
more doubts about the usefulness of any inva-
sive intervention.
Surgeons and cardiologists differed most
consistently in how they appraised CABG v
PTCA indications. We wondered if this differ-
ence depended on interactions between spe-
cialty and clinical factors, owing to differences
between surgeons and cardiologists in their
appreciation of the importance of these fac-
tors. We tested for this possibility by carrying
out for each clinical chapter two multiple
regression analyses of CABG v PTCA scores,
one with and one without interaction terms,
using the clinical factors defining the reference
model cases as input variables. Table 5
describes the reference model cases and pre-
sents the results of the analyses without inter-
action terms. Surgeons rated CABG v PTCA
indications higher than cardiologists for all of
the clinical chapters, suggesting stronger pref-
erence for CABG among surgeons or, in other
words, stronger preference for PTCA among
cardiologists if a procedure was to be done. In
analyses using interaction terms the CABG v
PTCA scores of the surgeons were not signifi-
cantly higher than those of the cardiologists for
the chapters “asymptomatic” and “acute
myocardial infarction”, except for a subset of
indications. Surgeons’ scores were higher for
model cases with one-vessel disease not
involving the PLAD in the chapter “asympto-
matic” and for model cases with cardiogenic
shock in the chapter “acute myocardial infarc-
tion”. For all other chapters the disparity in
scores between surgeons and cardiologists
remained significant when interaction terms
were added to the regression models.
However, this difference was not constant
across subsets of indications in each chapter.
In general there was little discrepancy in the
scores of surgeons and cardiologists for model
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Table 4 Clinical determinants of appropriateness scores for treatment indications for chronic stable angina cases
Regression coefficient@ (95% CI)
———————————————————————————————————————
Clinical factor¶ CABG v MED PTCA v MED CABG v PTCA
Anatomy#:
one-vessel, "PLAD "1·3 ("1·9 to "1·6)‡ 0·0 "0·7 ("0·9 to "0·5)‡
one-vessel, !PLAD 0·4 (0·2 to 0·7) 0·9 (0·6 to 1·1)‡ "0·7 ("0·9 to "0·4)‡
two-vessel, "PLAD¶ — — —
two-vessel, "PLAD 1·6 (1·4 to 1·9)‡ 0·5 (0·3 to 0·8)‡ 0·5 (0·3 to 0·8)‡
three-vessel 3·0 (2·7 to 3·3) 0·0 2·7 (2·5 to 3·0)‡
left main 5·5 (5·3 to 5·8)‡ "1·6 ("1·8 to "1·3)‡ 5·0 (4·7 to 5·2)‡
Lesion type:
A or B¶ — — —
C 0·0 "3·1 ("3·3 to "2·9)‡ 2·6 (2·5 to 2·7)‡
Anginal symptoms:
absent or I "1·3 ("1·5 to "1·1)‡ "0·9 ("1·1 to "0·7)‡ "0·2 ("0·4 to "0·1)‡
II* — —
III or IV 1·3 (1·1 to 1·4)‡ 1·1 (0·9 to 1·3)‡ 0·3 (0·2 to 0·5)‡
Medication:
adequate¶ — — —
not adequate "0·1 ("1·1 to "0·8)‡ "0·9 ("1·0 to "0·7)‡ "0·1 ("0·2 to "0·0)*
Exercise stress test:
positive¶ — — —
not positive "0·9 ("1·0 to "0·7)‡ "0·9 ("1·0 to "0·7)‡ 0·0 ("0·1 to 0·1)
Left ventricular dysfunction:
not severe¶ — — —
severe "0·6 ("0·7 to "0·4)‡ "0·3 ("0·5 to "0·1)‡ 0·0 ("0·1 to 0·1)
Peri-interventional risk:
not high¶ — — —
high "0·8 ("0·9 to "0·6)‡ "0·3 ("0·5 to "0·2)‡ "0·2 ("0·4 to "0·1)†
Constant¶ 4·8 (4·5 to 5·1) 5·8 (5·6 to 6·1) 2·8 (2·6 to 3·0)
¶The reference model case was characterised by the factor levels marked with this symbol, that is, a constant, two-vessel disease not
involving the PLAD, type A or B lesions, angina class II, adequate medication, with the outcome of an exercise stress test pointing
to ischaemia, no severe left ventricular dysfunction, and not at high peri-interventional risk. For the CABG v medical treatment indi-
cation (CABG-MED) this patient’s appropriateness score would be: 4·8!0!0!0!0!0!0!0 = 4·8. Scores for the reference case
represent values on a 1–9 scale.
@Computed with multiple linear regression analysis, not truncated. All values are differences relative to the score of the reference
case. 95% CI = 95% confidence interval. R2 values were 0·81, 0·89, and 0·91 for CABG v medical treatment, PTCA v medical treat-
ment, and CABG v PTCA indications, respectively.
#!PLAD and "PLAD , with and without involvement of the proximal lett anterior descending coronary artery, respectively.
*P < 0·05, †P < 0·01, ‡P < 0·001.
CABG, coronary artery bypass grafting; MED, medical treatment; PTCA, percutaneous transluminal coronary angioplasty.
CABG-MED, PTCA-MED, and CABG-PTCA: the three sets of indications.
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cases with left main disease or three-vessel dis-
ease and for model cases with type C lesions.
The greatest disparities were found for model
cases with one-vessel disease, where the ten-
dency of the surgeons to rate CABG v PTCA
indications higher than the cardiologists
amounted to a 1·5–2 points difference on the
1–9 scale for the chapters “chronic stable
angina” and “recent myocardial infarction”.
Finally, we averaged for each of the pan-
elists their ratings of all CABG v medical
treatment indications and all PTCA v medical
treatment indications. We then determined
the rank order of the panelists for each set of
indications, the one with the highest mean
score being placed in the first and the one with
the lowest score in the 12th position. The
results are shown in table 6. Numbers 1 and 2
in the table, a cardiologist and a surgeon,
ranked high on both sets of indications. These
two clinicians can be said to favour, at least on
paper, an aggressive practice style regardless of
the type of invasive intervention. In contrast,
members 11 and 12 made up the rear on both
CABG v medical treatment and PTCA v
medical treatment indication ratings, which
may correspond to a conservative style. Other
panel members, such as panelists 3, 4, and 6,
ranked high on the indications involving the
invasive intervention from their own specialty
but lower on the other indications.
Discussion
We asked a Dutch expert panel to rate the
appropriateness of indications for using
CABG and PTCA in hundreds of model
cases. Ideally, deciding whether indications
are appropriate or not should be based on the
outcomes of randomised clinical trials.
However, we cannot expect trials with their
strict selection of patients to address all clini-
cal permutations with sufficient precision to
provide guidance about how to treat all of the
cases seen in practice. Inevitably, physicians
must also rely on clinical judgement and infer-
ence. This is not to excuse physicians from
scrutinising and testing the effects of their
actions. Rendering clinical judgement explicit
should be integral to the practice of medicine.
The RAND/UCLA method provides a feasible
tool for this purpose.
The method may have limitations though.
One could wonder whether panelists are able
to rate large numbers of indications reliably
and consistently. The evidence is that panelists
are up to this task. In our study there was satis-
factory test-retest concordance for a random
sample of indications and others also have
found panel scores to be reliable.5 A potential
problem with group judgement methods is the
risk that the outcomes are biased by collective
error. This leads us to the issue of validity.
Construct validity reflects the degree to which
the features used to describe model cases are
relevant for clinical practice. The list of model
cases for CABG and PTCA appears to have
good construct validity. Not only did panels in
various countries select largely the same set of
clinical features,7–10 but an analysis of treat-
ment decisions in everyday practice also
showed that these and a few additional fea-
tures indeed influenced if not determined clin-
icians’ decision making.11 19 Moreover, the
scores of the DUCAT panel corresponded
well to clinical guidelines developed concur-
rently but independently on behalf of the
Netherlands Society of Cardiology.20 Content
validity is the degree in which the panel scores
accurately reflect the appropriateness of indi-
cations. There were no clear discrepancies
between the evidence in published reports at
the time of the panel meeting on the one hand
and the DUCAT panel scores on the other.
The key question is how valid the scores were
in the many cases where the evidence was
incomplete. One way to answer this question
is to look at research data that became avail-
able after the DUCAT panel met.
Since the panel meeting in 1991, results of
several randomised trials comparing PTCA
with medical treatment and PTCA with
CABG have been published.21–27 In the ACME
trial coronary angioplasty was better than
medical treatment in relieving angina at six
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Table 5 Choosing between CABG and PTCA: regression
analyses of difference in appropriateness scores between
surgeons and cardiologists by clinical chapter
Clinical chapter Difference¶
1 Asymptomatic 0·54‡
2 Chronic stable angina 0·57‡
3 Unstable angina 0·59‡
4 Acute myocardial infarction 0·92‡
5 Recent myocardial infarction 0·82‡
6 Near sudden death 0·29*
¶Differences in appropriateness scores expressed as values
relative to the scores for the reference cases (that is, the
constants of multiple regression analyses) on a 1–9 scale. The
higher the difference, the stronger the preference for CABG
among surgeons or, in other words, the stronger the preference
for PTCA among cardiologists.
Characteristics of reference model cases. Common to all cases:
two-vessel disease without involvement of the PLAD, type A
or B lesions, no severe left ventricular dysfunction, not at high
risk for peri-interventional complications. Additional features:
Asymptomatic, evidence of ischaemia on an exercise stress test.
Chronic stable angina, angina class II, adequate medication,
evidence of ischaemia on an exercise stress test. Unstable
angina, pain on adequate medication. Acute myocardial
infarction, continuing paint. Recent myocardial infarction, non-
Q-wave infarction, asymptomatic, no evidence of ischaemia on
an exercise stress test. Near sudden death, pain and/or evidence
of ischaemia on an exercise stress test.
*P < 0·05, ‡P < 0·001.
CABG, coronary artery bypass  grafting; PTCA, percuta-
neous transluminal coronary angioplasty; PLAD, proximal
left anterior descending coronary artery.
Table 6 Rank order of panelists based on their average ratings of all indications involving




Panelist¶ indications indications Sum@
1 Cardiologist 3 1 4
2 Surgeon 2 4 6
3 Cardiologist 7 2 9
4 Surgeon 1 9 10
5 Surgeon 5 6 11
6 Cardiologist 9 3 11
7 Surgeon 4 7 11
8 Cardiologist 8 5 13
9 Cardiologist 6 10 16
10 Surgeon 10 8 18
11 Cardiologist 11 11 22
12 Surgeon 12 12 24
¶Numbers in order of sum total.
@Sum of rank number for CABG indications and rank number for PTCA indications.
CABG, coronary artery bypass grafting; MED, medical treatment; PTCA, percutaneous trans-
luminal coronary angioplasty.
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months’ follow up and improving exercise tol-
erance in patients with one-vessel disease.21 It
remains to be seen whether these modest ben-
efits outweigh the procedure related complica-
tions of PTCA. The DUCAT panel favoured
medical treatment in one-vessel disease with-
out PLAD stenosis. A meta-analysis of results
from trials comparing PTCA with CABG in
patients with either one-vessel or multivessel
disease failed to show a treatment difference in
rates of death and non-fatal myocardial infarc-
tion during up to three years’ follow up.28
However, patients in the PTCA groups more
often had angina, took more antianginal drugs,
and required further revascularisation more
frequently. All investigators nevertheless
agreed that PTCA remains a suitable option
and a simple initial alternative to CABG.22–27
This conclusion does not run counter to the
opinions of the DUCAT panel. The panel pre-
dominantly preferred PTCA to CABG in one-
and two-vessel disease, and CABG to PTCA
in three-vessel disease (table 3). It should be
noted, though, that the indications rated by
the panel were not weighted for frequency of
occurrence in actual practice. Consequently,
these findings do not necessarily represent the
proportion of cases that would be found
appropriate or inappropriate in everyday prac-
tice.
Another issue is PLAD stenosis. The panel
considered PLAD stenosis to be important for
deciding between treatments. It more often
opted for invasive treatment in cases with one-
vessel disease with PLAD stenosis than in two-
vessel disease not including the PLAD (table
2). A review of the 10 year results from ran-
domised trials comparing CABG with medical
treatment,29 published after the panel meeting,
suggests that the panel was right. The review
renders it likely that patients with one-vessel
disease involving the PLAD benefit more from
surgery than those with two-vessel disease
without PLAD stenosis.
Taken together the results from recent trials
and meta-analyses support the views of the
DUCAT panel. However, the evidence for
how to treat many patients with coronary
artery disease is still incomplete and will prob-
ably remain so. It is likely that the majority of
model cases considered by the panel will never
be the subject of externally valid randomised
trials, and this is precisely why using appropri-
ateness methods is potentially so important,
for instance for formulating clinical practice
guidelines.
The best way to assess the validity of the
RAND/UCLA method is to relate panel scores
to patient outcomes. So far this has mainly
been done in retrospective studies in which the
medical records of patients were searched for
relevant information after the intervention had
taken place.5 30 31 Further proof of the validity
of the method may come from prospective
studies. One would expect patients with an
appropriate decision to fare better after the
intervention than similar patients with an
inappropriate decision.32 Some evidence to
this effect has come from a retrospective
cohort study.33 The DUCAT project includes
a prospective study of this sort.
The DUCAT panel scores were not free
from bias. Bias is apparent from the impact of
non-clinical factors such as the distinction
between cardiologists and surgeons. Also in
other panel studies physicians carrying out a
procedure tended to rate indications for that
procedure higher than those for alternative
procedures.34 The importance of these non-
clinical factors should not be exaggerated.
Although the number of inappropriate indica-
tions might even have been higher if non-clini-
cal factors had not been in effect, the DUCAT
panelists considered many indications to be
inappropriate. How one assesses the influence
of non-clinical factors such as panel composi-
tion depends in part on the goals one wishes to
accomplish with the RAND/UCLA method.35
One aim of DUCAT is to provide clinicians in
The Netherlands with a decision aiding tool fit
for use in the “bipartisan” (interventional car-
diology and cardiac surgery) environment of
specialised tertiary referral centres. As the
practice of medicine continues to evolve, this
tool can be used to trace and monitor changes
in medical practice and to update professional
policies regarding indication setting.
This work was part of the DUCAT (Dutch inventory of inva-
sive coronary atherosclerosis treatments) study, funded by the
National Health Insurance Board (Ziekenfondsraad) in The
Netherlands. The study design was approved by the medical
ethics committee of the University Hospital Dijkzigt in
Rotterdam. The panel members were J J R M Bonnier, T
Ebels, J M P G Ernst, Th R van Geldorp, L A van Herwerden,
G J Laarman, B A J M de Mol, N H J Pijls, K B Prenger, G L
van Rijk-van Zwikker, P W Westerhof, and F Zijlstra.
Appendix
DEFINITIONS OF CLINICAL CHAPTERS
Asymptomatic, patients with significant coronary artery
disease without a history of angina, or who have no
angina on their current medical regimen for more than
three months, or who have sustained a myocardial
infarction more than 30 days ago with no recurrence of
angina for at least three weeks.
Chronic stable angina, patients meeting three of four con-
ditions: (1) substernal or left sided chest pain; (2) radia-
tion of pain to the left arm, left side of the neck, or left
jaw; (3) the pain is usually precipitated by exercise; (4)
the pain is relieved within 10 minutes by rest or sublingual
glyceryl trinitrate.
Unstable angina, chest pain thought to be due to myocar-
dial ischaemia requiring hospital admission because of
difficulty in control or concern about the possibility of
myocardial infarction, including (1) recent increase in
the intensity, frequency, or duration of chronic angina;
(2) the development of angina at rest; or (3) new onset
of severe chest pain.
Acute myocardial infarction, infarction within 24 hours.
Recent myocardial infarction, infarction between 1 and 30
days.
Near sudden death, patients who are presumed to have
sustained a cardiac arrest without evidence of a myocar-
dial infarction.
CABG and valve surgery, bypass grafting done concur-
rently with valve surgery.
Palliative PTCA, PTCA as palliative treatment in
patients with non-cardiac terminal disease who would
not be considered candidates for bypass surgery in the
event of PTCA failure.
CLINICAL CHARACTERISTICS NOT DEFINED IN THE TEXT
OR IN CITED REFERENCES
Significant coronary artery disease, at least 50% stenosis
in the left main artery; at least 70% stenosis in one
artery in case of one-vessel disease; at least 70% stenosis
Indications for coronary revascularisation: a Dutch perspective 217
 on 13 December 2006 heart.bmj.comDownloaded from 
in one artery and 50% in other arteries in case of multi-
vessel disease.
Adequate medication, chronic stable angina: patient
receives or has received drugs from three classes of
medication: β blockers, calcium channel antagonists,
and long acting nitrates, or less as far as justified by the
presence of contraindications; unstable angina: patient
receives or has received drugs from the same three
classes of medication and receives intravenous heparin
and/or intravenous glyceryl trinitrate, unless con-
traindicated.
Severe left ventricular dysfunction, ejection fraction
< 20%.
Stress test, any exercise stress test or stress imaging
study; positive outcome: ST depression equal or
greater than 1 mm (exercise test), or total or partial
reversible defect in one arterial territory (imaging
study). The outcome of the stress test was considered
to be “not positive” if the test was performed and had a
negative or indeterminate result or if the test was not
performed.
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